Coherus Oncology, Inc. Common Stock
Veridion Score
Composite trend over time
Why is CHRS moving today?
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CHRS.
CHRS insider activity
Coherus Oncology, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$21K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-22 | 2026-01-20 | McMichael Bryan J | Insider | sell | $1.55 | 1,715 | 21,236 | $3K | SEC Form 4 |
| 2026-01-22 | 2026-01-20 | Lanfear Dennis M | Insider | sell | $1.55 | 11,839 | 673,235 | $18K | SEC Form 4 |
CHRS contract awards, year to date.
Public federal awards linked to this ticker.
CHRS lobbying filings, year to date.
Registered lobbying filings matched to Coherus Oncology, Inc. Common Stock.